{"entity":{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","aka":["TCTN"],"tldr":"A phase 3 trial of epirubicin, cyclophosphamide and carboplatin in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, active but no longer recruiting.","summary":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer is a phase 3, randomised interventional study registered as NCT02455141 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 786 participants, started 2016-03 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin plus Cyclophosphamide; Taxanes; Taxanes plus Carboplatin. Conditions listed: Breast Neoplasm. Triple-negative eligibility wording from the registry: \"* Tumor specimens are available for estrogen receptor (ER), progesterone receptor (PgR) and Her2 (human epidermal-growth-factor receptor 2) detection, patients should be with triple negative breast cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02455141","url":"https://clinicaltrials.gov/study/NCT02455141"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["epirubicin","cyclophosphamide","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02455141","phase":"3","setting":"Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial","sponsor":"Shanghai Jiao Tong University School of Medicine","enrolled":786,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02455141/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}